🇺🇸 Carboplatinum in United States

92 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Malignant Neoplasm Progression — 12 reports (13.04%)
  2. Disease Progression — 11 reports (11.96%)
  3. Diarrhoea — 10 reports (10.87%)
  4. Alopecia — 9 reports (9.78%)
  5. Death — 9 reports (9.78%)
  6. Off Label Use — 9 reports (9.78%)
  7. Decreased Appetite — 8 reports (8.7%)
  8. Haematotoxicity — 8 reports (8.7%)
  9. Nausea — 8 reports (8.7%)
  10. Product Use In Unapproved Indication — 8 reports (8.7%)

Source database →

Other Other approved in United States

Frequently asked questions

Is Carboplatinum approved in United States?

Carboplatinum does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Carboplatinum in United States?

Universitair Ziekenhuis Brussel is the originator. The local marketing authorisation holder may differ — check the official source linked above.